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Genetic variants in novel pathways influence blood
pressure and cardiovascular disease risk
The International Consortium for Blood Pressure Genome-Wide Association Studies
Blood pressure is a heritable trait1 influenced by several biological
pathways and responsive to environmental stimuli. Over one
billion people worldwide have hypertension ($140mmHg systolic
blood pressure or$90mmHg diastolic blood pressure)2. Even
small increments in blood pressure are associated with an
increased risk of cardiovascular events3. This genome-wide asso-
ciation study of systolic and diastolic blood pressure, which used
a multi-stage design in 200,000 individuals of European descent,
identified sixteen novel loci: six of these loci contain genes
previously known or suspected to regulate blood pressure
(GUCY1A3–GUCY1B3, NPR3–C5orf23, ADM, FURIN–FES,
GOSR2, GNAS–EDN3); the other ten provide new clues to blood
pressure physiology. A genetic risk score based on 29 genome-
wide significant variants was associated with hypertension, left
ventricular wall thickness, stroke and coronary artery disease,
but not kidney disease or kidney function. We also observed asso-
ciations with blood pressure in East Asian, South Asian and
African ancestry individuals. Our findings provide new insights
into the genetics and biology of blood pressure, and suggest
potential novel therapeutic pathways for cardiovascular disease
prevention.
Genetic approaches have advanced the understanding of biological
pathways underlying inter-individual variation in blood pressure. For
example, studies of rare Mendelian blood pressure disorders have
identified multiple defects in renal sodium handling pathways4.
More recently two genome-wide association studies (GWAS), each
of .25,000 individuals of European ancestry, identified 13 loci asso-
ciated with systolic blood pressure (SBP), diastolic blood pressure
(DBP) and hypertension5,6. We now report results of a new meta-
analysis of GWAS data that includes staged follow-up genotyping to
identify additional blood pressure loci.
Primary analyses evaluated associations between 2.5 million geno-
typed or imputed single nucleotide polymorphisms (SNPs) and SBP
and DBP in 69,395 individuals of European ancestry from 29 studies
(Supplementary Materials sections 1–3 and Supplementary Tables 1
and 2). Following GWAS meta-analysis, we conducted a three-stage
validation experiment that made efficient use of available genotyping
resources, to follow up top signals in up to 133,661 additional indivi-
duals of European descent (Supplementary Fig. 1 and Supplementary
Materials section 4). Twenty-nine independent SNPs at 28 loci were
significantly associated with SBP, DBP, or both in the meta-analysis
combining discovery and follow-up data (Fig. 1, Table 1, Supplemen-
tary Figs 2, 3 and Supplementary Tables 3–5). All 29 SNPs attained
association P, 53 1029, an order of magnitude beyond the standard
genome-wide significance level for a single-stage experiment (Table 1).
Sixteen of these 29 associations were novel (Table 1). Two associa-
tions were near the FURIN and GOSR2 genes; prior targeted analyses
of variants in these genes suggested they may be blood pressure loci7,8.
At the CACNB2 locus we validated association for a previously
reported6 SNP, rs4373814, and detected a novel independent asso-
ciation for rs1813353 (pairwise r2 5 0.015 in HapMap CEU). Of our
13 previously reported associations5,6, only the association at PLCD3
was not supported by the current results (Supplementary Table 4).
Some of the associations are in or near genes involved in pathways
known to influence blood pressure (NPR3, GUCY1A3–GUCY1B3,
ADM, GNAS–EDN3, NPPA–NPPB and CYP17A1; Supplementary
Fig. 4). Twenty-two of the 28 loci did not contain genes that were a
priori strong biological candidates.
As expected from prior blood pressure GWAS results, the effects of
the novel variants on SBP andDBPwere small (Fig. 1 and Table 1). For
all variants, the observed directions of effects were concordant for SBP,
DBP and hypertension (Fig. 1, Table 1 and Supplementary Fig. 3).
Among the genes at the genome-wide significant loci, only CYP17A1,
previously implicated inMendelian congenital adrenal hyperplasia and
hypertension, is known to harbour rare variants that have large effects
on blood pressure9.
We performed several analyses to identify potential causal alleles
and mechanisms. First, we looked up the 29 genome-wide significant
index SNPs and their close proxies (r2. 0.8) among cis-acting expres-
sion SNP (eSNP) results from multiple tissues (Supplementary
Materials section 5). For 13/29 index SNPs, we found an association
between nearby eSNP variants and the expression levels of at least one
gene transcript (1024.P. 10251; Supplementary Table 6). In five
cases, the index blood pressure SNP and the best eSNP from a genome-
wide survey were identical, highlighting potential mediators of the
SNP–blood pressure associations.
Second, because changes in protein sequence are a priori strong
functional candidates, we sought non-synonymous coding SNPs that
were in high linkage disequilibrium (r2. 0.8) with the 29 index SNPs.
We identified such SNPs at eight loci (Table 1, Supplementary
Materials section 6 and Supplementary Table 7). In addition we per-
formed analyses testing for differences in genetic effect according to
body mass index (BMI) or sex, and analyses of copy number variants,
pathway enrichment and metabolomic data, but we did not find any
statistically significant results (Supplementary Materials sections 7–9
and Supplementary Tables 8–10).
We evaluated whether the blood pressure variants we identified
in individuals ofEuropeanancestrywere associatedwith bloodpressure
in individuals of East Asian (N5 29,719), South Asian (N5 23,977)
and African (N5 19,775) ancestries (Table 1 and Supplementary
Tables 11–13). We found significant associations in individuals of
East Asian ancestry for SNPs at nine loci and in individuals of South
Asian ancestry for SNPs at six loci; some have been reported previously
(Supplementary Tables 12 and 15). The lack of significant association
for individual SNPs may reflect small sample sizes, differences in allele
frequencies or linkage disequilibrium patterns, imprecise imputation
for some ancestries using existing reference samples, or a genuinely
different underlying genetic architecture. Because of limited power to
detect effects of individual variants in the smaller non-European sam-
ples,we created genetic risk scores for SBP andDBP incorporating all 29
blood pressure variants weighted according to effect sizes observed
in the European samples. In each non-European ancestry group, risk
scores were strongly associated with SBP (P5 1.13 10240 in East
Asian, P5 2.93 10213 in South Asian, P5 9.83 1024 in African
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ancestry individuals) and DBP (P5 2.93 10248, P5 9.53 10215 and
P5 5.33 1025, respectively; Supplementary Table 13).
We also created a genetic risk score to assess association of the
variants in aggregate with hypertension and with clinical measures
of hypertensive complications including left ventricular mass, left
ventricular wall thickness, incident heart failure, incident and preval-
ent stroke, prevalent coronary artery disease (CAD), kidney disease
and measures of kidney function, using results from other GWAS
consortia (Table 2, Supplementary Materials sections 10, 11 and
Supplementary Table 14). The risk score was weighted using the aver-
age of SBP and DBP effects for the 29 SNPs. In an independent sample
of 23,294women10, an increase of one standard deviation in the genetic
risk score was associated with a 23% increase in the odds of hyperten-
sion (95% confidence interval 19–28%; Table 2 and Supplementary
Table 14). Among individuals in the top decile of the risk score, the
prevalence of hypertensionwas 29%comparedwith 16% in the bottom
decile (odds ratio 2.09, 95% confidence interval 1.86–2.36). Similar
results were observed in an independent hypertension case-control
sample (Table 2). In our study, individuals in the top compared to
bottom quintiles of genetic risk score differed by 4.6mmHg SBP and
3.0mmHgDBP, differences that approach population-averaged blood
pressure treatment effects for a single antihypertensive agent11.
Epidemiological data have shown that differences in SBP and DBP
of this magnitude, across the population range of blood pressure,
are associated with an increase in cardiovascular disease risk3.
Consistent with this and in line with findings from randomized trials
of blood-pressure-lowering medication in hypertensive patients12,13,
the genetic risk score was positively associated with left ventri-
cular wall thickness (P5 6.03 1026), occurrence of stroke
(P5 3.33 1025) and CAD (P5 8.13 10229). The same genetic risk
score was not, however, significantly associated with chronic kidney
disease or measures of kidney function, even though these renal out-
comes were available in a similar sample size as for the other outcomes
(Table 2). The absence of association with kidney phenotypes could be
explained by a weaker causal relationship between blood pressure and
kidney phenotypes than with CAD and stroke. This finding is consist-
ent with themismatch between observational data that show a positive
association of blood pressurewith kidney disease, and clinical trial data
that show inconsistent evidence of a benefit from blood pressure low-
ering on kidney disease prevention in patients with hypertension14.
Thus, several lines of evidence converge to indicate that blood pressure
elevation may in part be a consequence rather than a cause of sub-
clinical kidney disease.
Our discovery meta-analysis (Supplementary Fig. 2) suggests an
excess ofmodestly significant (1025,P, 1022) associations probably
arising from common blood pressure variants of small effect. By divid-
ing our principal GWAS data set into non-overlapping discovery
(N< 56,000) and validation (N< 14,000) subsets, we found robust
evidence for the existence of such undetected common variants
(Supplementary Fig. 5 and Supplementary Materials section 12). We
estimate15 that there are 116 (95% confidence interval 57–174) inde-
pendent blood pressure variants with effect sizes similar to those
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Figure 1 | Genome-wide 2log10 P-value plots and effects for significant
loci. a, b, Genome-wide 2log10 P-value plots are shown for SBP (a) and DBP
(b). SNPs within loci reaching genome-wide significance are labelled in red for
SBP and blue for DBP (62.5Mb of lowest P value) and lowest P values in the
initial genome-wide analysis as well as the results of analysis including
validation data are labelled separately. The lowest P values in the initial GWAS
are denoted with a X. The range of different sample sizes in the final meta-
analysis including the validation data are indicated as: circle (96,000–140,000),
triangle (.140,000–180,000) and diamond (.180,000–220,000). SNPs near
unconfirmed loci are in black. The horizontal dotted line is P5 2.5 3 1028.
GUCY denotes GUCY1A3–GUCY1B3. c, Effect size estimates and 95%
confidence bars per blood-pressure-increasing allele of the 29 significant
variants for SBP (red) and DBP (blue). Effect sizes are expressed in mmHg per
allele.
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reported here, which collectively can explain,2.2% of the phenotypic
variance for SBP and DBP, compared with 0.9% explained by the 29
associations discovered thus far (Supplementary Fig. 6 and Sup-
plementary Materials section 13).
Most of the 28 blood pressure loci harbour multiple genes
(Supplementary Table 15 and Supplementary Fig. 4), and although
substantial research is required to identify the specific genes and var-
iants responsible for these associations, several loci contain highly
plausible biological candidates. The NPPA and NPPB genes at the
MTHFR–NPPB locus encode precursors for atrial- and B-type
natriuretic peptides (ANP, BNP), and previous work has identified
SNPs—modestly correlated with our index SNP at this locus—which
are associated with plasmaANP, BNP and blood pressure16.We found
the index SNP at this locus was associated with opposite effects on
blood pressure and on ANP/BNP levels, consistent with a model in
which the variants act through increased ANP/BNP production to
lower blood pressure16 (Supplementary Materials section 14).
Two other loci identified in the current study harbour genes
involved in natriuretic peptide and related nitric oxide signalling path-
ways17,18, both of which act to regulate cyclic guanosine monopho-
sphate. The first locus contains NPR3, which encodes the natriuretic
peptide clearance receptor (NPR-C). NPR3 knockout mice exhibit
reduced clearance of circulating natriuretic peptides and lower blood
pressure19. The second locus includes GUCY1A3 and GUCY1B3,
encoding the a and b subunits of soluble guanylate cyclase; knockout
of either gene in murine models results in hypertension20.
Another locus contains ADM—encoding adrenomedullin—which
has natriuretic, vasodilatory andblood-pressure-lowering properties21.
At the GNAS–EDN3 locus, ZNF831 is closest to the index SNP, but
GNAS and EDN3 are two nearby compelling biological candidates
(Supplementary Fig. 4 and Supplementary Table 15).
We identified two loci with plausible connections to blood pressure
via genes implicated in renal physiology or kidney disease. At the first
locus, SLC4A7 is an electro-neutral sodiumbicarbonate co-transporter
expressed in the nephron and in vascular smooth muscle22. At
the second locus, PLCE1 (phospholipase-C-epsilon-1 isoform) is
important for normal podocyte development in the glomerulus;
sequence variation in PLCE1 has been implicated in familial nephrotic
syndromes and end-stage kidney disease23.
Missense variants in two genes involved inmetal ion transport were
associated with blood pressure in our study. The first encodes a His/
Asp change at amino acid 63 (H63D) inHFE and is a low-penetrance
allele for hereditary hemochromatosis24. The second is an Ala/Thr
polymorphism located in exon 7 of SLC39A8, which encodes a zinc
transporter that also transports cadmium and manganese25. The same
allele of SLC39A8 associated with blood pressure in our study has
recently been associated with high-density lipoprotein cholesterol
levels26 and BMI27 (Supplementary Table 15).
We have shown that 29 independent genetic variants influence
blood pressure in people of European ancestry. The variants reside
in 28 loci, 16 of which were novel, and we confirmed association of
several of them in individuals of non-European ancestry. A risk score
Table 1 | Summary association results for 29 blood pressure SNPs
Locus Index SNP Chr Position CA/
NCA
CAF nsSNP eSNP SBP DBP HTN
Beta P value Effect in
EA/SA/A
Beta P value Effect in
EA/SA/A
Beta P value
MOV10 rs2932538 1 113,018,066 G/A 0.75 Y(p) Y(p) 0.388 1.2 31029 1/1/2 0.240 9.9 310210 1/1*/2 0.049 2.9 31027
SLC4A7 rs13082711 3 27,512,913 T/C 0.78 Y(p) Y(p) -0.315 1.5 31026 2/2/1 20.238 3.8 31029 2/2/1 20.035 3.6 31024
MECOM rs419076 3 170,583,580 T/C 0.47 - - 0.409 1.8 310213 1/1/1 0.241 2.1 310212 1/1/2 0.031 3.1 31024
SLC39A8 rs13107325 4 103,407,732 T/C 0.05 Y Y(1) -0.981 3.3 310214 ?/1/1 20.684 2.3 310217 ?/1/1 20.105 4.9 31027
GUCY1A3–
GUCY1B3
rs13139571 4 156,864,963 C/A 0.76 - - 0.321 1.2 31026 1/2/1 0.260 2.2 310210 1/2/1 0.042 2.5 31025
NPR3–
C5orf23
rs1173771 5 32,850,785 G/A 0.60 - - 0.504 1.8 310216 1*/1/1 0.261 9.1 310212 1*/1/2 0.062 3.2 310210
EBF1 rs11953630 5 157,777,980 T/C 0.37 - - -0.412 3.0 310211 1/1/1 20.281 3.8 310213 1/1/1 20.052 1.7 31027
HFE rs1799945 6 26,199,158 G/C 0.14 Y - 0.627 7.7 310212 1/1/2 0.457 1.5 310215 1/1/2 0.095 1.8 310210
BAT2–BAT5 rs805303 6 31,724,345 G/A 0.61 Y(p) Y(1) 0.376 1.5 310211 2/2/? 0.228 3.0 310211 2/2/1 0.054 1.1 310210
CACNB2(59) rs4373814 10 18,459,978 G/C 0.55 - - -0.373 4.8 310211 1/1/2 20.218 4.4 310210 2/1/2 20.046 8.5 31028
PLCE1 rs932764 10 95,885,930 G/A 0.44 - - 0.484 7.1 310216 1/1/2 0.185 8.1 31027 1/1/2 0.055 9.4 31029
ADM rs7129220 11 10,307,114 G/A 0.89 - - -0.619 3.0 310212 ?/-/1 20.299 6.4 31028 ?/2/1 20.044 1.1 31023
FLJ32810–
TMEM133
rs633185 11 100,098,748 G/C 0.28 - - -0.565 1.2 310217 1*/1/1 20.328 2.0 310215 1*/1/2 20.070 5.4 310211
FURIN–FES rs2521501 15 89,238,392 T/A 0.31 - Y(2) 0.650 5.2 310219 1*/1/1 0.359 1.9 310215 1*/1/1 0.059 7.0 31027
GOSR2 rs17608766 17 42,368,270 T/C 0.86 - Y(1) -0.556 1.1 310210 1/2/1 20.129 0.017 1/2/1 20.025 0.08
JAG1 rs1327235 20 10,917,030 G/A 0.46 - - 0.340 1.9 31028 1*/1/1 0.302 1.4 310215 1*/1*/1 0.034 4.6 31024
GNAS–EDN3 rs6015450 20 57,184,512 G/A 0.12 Y(p) - 0.896 3.9 310223 ?/1/1 0.557 5.6 310223 ?/1*/1 0.110 4.2 310214
MTHFR–
NPPB
rs17367504 1 11,785,365 G/A 0.15 - Y(2/r) -0.903 8.7 310222 1/1/1 20.547 3.5 310219 1/1/1 20.103 2.3 310210
ULK4 rs3774372 3 41,852,418 T/C 0.83 Y Y(r/p) -0.067 0.39 2/2/1 20.367 9.0 310214 1/1/1 20.017 0.18
FGF5 rs1458038 4 81,383,747 T/C 0.29 - - 0.706 1.5 310223 1*/1/1 0.457 8.5 310225 1*/1*/1 0.072 1.9 31027
CACNB2(39) rs1813353 10 18,747,454 T/C 0.68 - - 0.569 2.6 310212 1/1/1 0.415 2.3 310215 1/1/1 0.078 6.2 310210
C10orf107 rs4590817 10 63,137,559 G/C 0.84 - Y(r) 0.646 4.0 310212 2/1/2 0.419 1.3 310212 2/2/2 0.096 9.8 31029
CYP17A1–
NT5C2
rs11191548 10 104,836,168 T/C 0.91 - Y(2) 1.095 6.9 310226 1*/1*/1 0.464 9.4 310213 1*/1*/1 0.097 1.4 31025
PLEKHA7 rs381815 11 16,858,844 T/C 0.26 - - 0.575 5.3 310211 1*/1/1 0.348 5.3 310210 1*/2/1 0.062 3.4 31026
ATP2B1 rs17249754 12 88,584,717 G/A 0.84 - - 0.928 1.8 310218 1*/1*/2 0.522 1.2 310214 1*/1*/2 0.126 1.1 310214
SH2B3 rs3184504 12 110,368,991 T/C 0.47 Y Y(1) 0.598 3.8 310218 2/2/1 0.448 3.6 310225 2/2/1 0.056 2.6 31026
TBX5–TBX3 rs10850411 12 113,872,179 T/C 0.7 - - 0.354 5.4 31028 2/1/2 0.253 5.4 310210 2/2/2 0.045 5.2 31026
CYP1A1–
ULK3
rs1378942 15 72,864,420 C/A 0.35 - Y(1) 0.613 5.7 310223 1*/1/1 0.416 2.7 310226 1*/1/2 0.073 1.0 31028
ZNF652 rs12940887 17 44,757,806 T/C 0.38 - Y(2) 0.362 1.8 310210 1/2/1 0.27 2.3 310214 1/2/1 0.046 1.2 31027
Summary association statistics, based on combined discovery and follow-up data, for 29 independent SNPs in individuals of European ancestry are shown. New genome-wide significant findings (17 SNPs) are
presented in the tophalf of the table, data on12previouslypublished signals are presented in the lowerhalf. Y indicates that thebloodpressure index SNP is anon-synonymous (ns)SNP, Y(p) indicates a proxySNP
is a nsSNP. Y(1) indicates that the blood pressure index SNP is the strongest known eSNP for a transcript; Y(2) indicates that the blood pressure index SNP is an eSNP but not the strongest known eSNP for any
transcript. Y(r) indicates that thebloodpressure indexSNP is the strongest knowneSNP ina targeted real-timePCRexperiment. Y(p) indicates that a proxySNP (r2.0.8) to abloodpressureSNP is an eSNPbutnot
the strongest known eSNP. Observed effect directions in East Asian (EA), South Asian (SA) and African (A) ancestry individuals are coded 1 or 2 if concordant or discordant with directions in European ancestry
results. Effect size estimates (beta) correspond to mmHg per coded allele for SBP and DBP and ln(odds) per coded allele for hypertension (HTN). CA, coded allele; CAF, coded allele frequency; NCA, non-coded
allele. ? denotes missing data. Genomic positions use NCBI Build 36 coordinates.
*Significant, controlling the FDR at 5% over 58 tests per ancestry (Supplementary Tables 5 and 12).
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derived from the 29 variants was significantly associated with blood-
pressure-related organ damage and clinical cardiovascular disease, but
not kidney disease. These loci improve our understanding of the gen-
etic architecture of blood pressure, provide new biological insights into
blood pressure control andmay identify novel targets for the treatment
of hypertension and the prevention of cardiovascular disease.
Note added in proof: Since thismanuscriptwas submitted, Kato et al.
published a blood pressure GWAS in East Asians that identified a SNP
highly correlated to the SNP we report at the NPR3/C5orf23 locus28.
METHODS SUMMARY
Supplementary Materials provide complete methods and include the following
sections: study recruitment and phenotyping, adjustment for antihypertensive
medications, genotyping, data quality control, genotype imputation, within-
cohort association analyses, meta-analyses of discovery and validation stages,
stratified analyses by sex and BMI, identification of eSNPs and non-synonymous
SNPs, metabolomic and lipidomic analyses, CNV analyses, pathway analyses,
analyses for non-European ancestries, association of a risk scorewith hypertension
and cardiovascular disease, estimation of numbers of undiscovered variants, mea-
surement of natriuretic peptides, and brief literature reviews and GWAS database
lookups of all validated blood pressure loci. Full GWAS results for <2.5 million
SNPs are also provided.
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